Gastrointestinal Cancer | Specialty

Lenz Highlights Ongoing Advances in mCRC

October 17th 2018

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

FDA Grants Olaparib Orphan Drug Designation for Pancreatic Cancer

October 17th 2018

The FDA has granted olaparib an orphan drug designation for the treatment of patients with pancreatic cancer.

Dr. Iqbal on Treatment Options for Patients With Neuroendocrine Tumors

October 17th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses treatment options for patients with neuroendocrine tumors (NETs).

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

Dr. Lenz on the Changing Landscape of Metastatic Colorectal Cancer

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

Dr. Barzi on Surgical Advances in Pancreatic Cancer

October 12th 2018

Afsaneh Barzi, MD, assistant professor of clinical medicine, USC Norris Comprehensive Cancer Center, discusses surgical advances in the treatment of patients with pancreatic cancer.

ESMO Asia mCRC Guidelines: Insights on Impact and Uptake

October 12th 2018

Dr. McCollum on Maintenance Therapy for Metastatic CRC

October 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.

Dr. Singal on the Potential for Immunotherapy in HCC

October 9th 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the potential of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Dr. Becerra Discusses Dosing Strategies in CRC

October 5th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Oncolytic Virus Explored in Advanced HCC

October 5th 2018

Ghassan K. Abou-Alfa, MD, discusses the potential of the oncolytic virus Pexa-Vec and other developments in hepatocellular carcinoma.

Fuchs Illuminates Associations Between Cancer, Lifestyle Habits

October 4th 2018

Charles S. Fuchs, MD, MPH, has investigated associations between lifestyle choices of food and exercise and cancer diagnosis and survivorship, leading to important insights that have clarified the relative value of diets that include nuts, alcohol, and legumes, among other foods.

Dr. Pinato on PD-L1 Testing in HCC

October 2nd 2018

David J. Pinato, MD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses the role of PD-L1 testing in hepatocellular carcinoma.

Dr. Cheng on the Need For Biomarkers in HCC

September 28th 2018

Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.

Later Lines of Therapy for Metastatic Colorectal Cancer

September 28th 2018

Future Management of Metastatic Colorectal Cancer

September 28th 2018

Emerging Therapy in Metastatic Colorectal Cancer

September 28th 2018

BEACON Trial: Triplet Therapy in BRAF V600E

September 28th 2018

Other I-O Approaches to Metastatic Colorectal Cancer

September 28th 2018

I-O Therapy in mCRC: Ipilimumab + Nivolumab

September 28th 2018